Study summary
An immunotherapy plus targeted pill shrank about half of treated adrenal cancers
52%had their tumors shrink
What was tested
Camrelizumab, an immunotherapy, with apatinib, a pill that blocks tumor blood vessels, in advanced adrenocortical carcinoma that had grown after earlier treatment. China, no comparison group.
What they found
- Tumors shrank in 52%, and 95% had their cancer shrink or hold steady.
- Median time before the cancer grew was 13.3 months; median survival 20.9 months.
- Liver enzyme rises were the most common serious side effect.
What it means
Among the best results reported in this cancer after standard treatment. Needs confirmation in a larger trial.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.